PA8429301A1 - BIARYLACETYLENE AS INHIBITORS OF MATRIX METALOPROTEASE. - Google Patents

BIARYLACETYLENE AS INHIBITORS OF MATRIX METALOPROTEASE.

Info

Publication number
PA8429301A1
PA8429301A1 PA19978429301A PA8429301A PA8429301A1 PA 8429301 A1 PA8429301 A1 PA 8429301A1 PA 19978429301 A PA19978429301 A PA 19978429301A PA 8429301 A PA8429301 A PA 8429301A PA 8429301 A1 PA8429301 A1 PA 8429301A1
Authority
PA
Panama
Prior art keywords
compounds
disorders
disease
pharmaceutical compositions
diseases
Prior art date
Application number
PA19978429301A
Other languages
Spanish (es)
Inventor
Jinshan Chen
Brian R Dixon
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of PA8429301A1 publication Critical patent/PA8429301A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/76Unsaturated compounds containing keto groups
    • C07C59/90Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

SE PRESENTAN COMPUESTOS INHIBITORIOS DE LA METALOPROTEASA DE MATRIZ, COMPOSICIONES FARMACEUTICAS DE LOS MISMOS Y UN METODO PARA TRATAR ENFERMEDADES QUE EMPLEA DICHOS COMPUESTOS. LOS COMPUESTOS DE LA PRESENTE INVENCION TIENEN LA FORMULA GENERALIZADA: DONDE R15 ES SELECCIONADO ENTRE EL GRUPO QUE CONSISTE EN HOCH2 MEOCH2, (N-PR)2NCH2, CH3CO2CH2, ETOCO2CH2,HO(CH2)2, CH3CO2(CH2)2, HO2C(CH2)2, OHC(CH2)3, HO(CH2)4PH,3-HO-PH, Y PHCH2OCH2; Y R16 ES: ESTOS COMPUESTOS SON UTILES PARA INHIBIR LAS METALOPROTEASAS DE MATRIZ Y, POR LO TANTO, PARA COMBATIR LOS TRASTORNOS A LOS CUALES CONTRIBUYEN LAS MMP, TALES COMO LA OSTEOARTRITIS, LA ARTRITIS REUMATOIDEA, LA ARTRITIS SEPTICA, LAS ENFERMEDADES PERIODONTALES, LAS ULCERAS DE CORNEA, LA PROTEINURIA, LA ENFERMEDAD DE ANEURISMA AORTICO, LA EPIDERMOLISIS VESICULAR DISTROFICA, LOS TRASTORNOS QUE PRODUCEN RESPUESTAS INFLAMATORIAS, LAS OSTEOPENIAS EN LAS QUE MEDIA LA ACTIVIDAD DE MMP, LA ENFERMEDAD DE LA ARTICULACION TEMPOROMANDIBULAR, LAS ENFERMEDADES DESMIELINIZANTES DEL SISTEMA NERVIOSO; LAS METASTASIS DE TUMORES O LA PERDIDA DEGENERATIVA DE CARTILAGO POSTERIOR A LA LESION ARTICULAR TRAUMATICA, Y LA TROMBOSIS CORONARIA A PARTIR DE LA RUPTURA DE PLACA ATEROESCLEROTICA. LA PRESENTE INVENCION PRESENTA ASIMISMO COMPOSICIONES FARMACEUTICAS Y METODOS PARA TRATAR DICHOS TRASTORNOS.INHIBITORY COMPOUNDS OF MATRIX METALOPROTEASE, PHARMACEUTICAL COMPOSITIONS OF THE SAME, AND A METHOD FOR TREATING DISEASES THAT USE THESE COMPOUNDS ARE PRESENTED. THE COMPOUNDS OF THE PRESENT INVENTION HAVE THE GENERALIZED FORMULA: WHERE R15 IS SELECTED FROM THE GROUP THAT CONSISTS OF HOCH2 MEOCH2, (N-PR) 2NCH2, CH3CO2CH2, ETOCO2CH2, HO (CH2) 2, CH3CO2 (CH2) 2, HO2 ) 2, OHC (CH2) 3, HO (CH2) 4PH, 3-HO-PH, AND PHCH2OCH2; AND R16 IS: THESE COMPOUNDS ARE USEFUL FOR INHIBITING MATRIX METALLOPROTEASES AND THEREFORE, TO COMBAT DISORDERS TO WHICH MMP CONTRIBUTE, SUCH AS OSTEOARTHRITIS, RHEUMETHETIC ARTHRITIS, SEPTIAL URETHRITIS CORNEA, PROTEINURIA, AORTIC ANEURISM DISEASE, DYSSTROPHIC VESICULAR EPIDERMOLISIS, DISORDERS THAT PRODUCE INFLAMMATORY RESPONSES, OSTEOPENIAS IN THE ACTIVITY OF THE SLEEPING DISEASES, THE ILLNESS OF THE TEMPOROMARIUS DISEASE THE METASTASIS OF TUMORS OR THE DEGENERATIVE LOSS OF CARTILAGO AFTER TRAUMATIC ARTICULAR INJURY, AND CORONARY THROMBOSIS FROM THE RUPTURE OF ATEROSCLEROTIC PLATE. THE PRESENT INVENTION ALSO PRESENTS PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING SUCH DISORDERS.

PA19978429301A 1996-05-15 1997-05-12 BIARYLACETYLENE AS INHIBITORS OF MATRIX METALOPROTEASE. PA8429301A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64502896A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
PA8429301A1 true PA8429301A1 (en) 2000-05-24

Family

ID=24587368

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19978429301A PA8429301A1 (en) 1996-05-15 1997-05-12 BIARYLACETYLENE AS INHIBITORS OF MATRIX METALOPROTEASE.

Country Status (18)

Country Link
EP (1) EP0912496A1 (en)
JP (1) JP3090957B2 (en)
CN (1) CN1139570C (en)
AR (1) AR007097A1 (en)
AU (1) AU710759B2 (en)
BR (1) BR9709077A (en)
CA (1) CA2253796C (en)
CO (1) CO5080759A1 (en)
HN (1) HN1997000088A (en)
HR (1) HRP970245B1 (en)
ID (1) ID16910A (en)
PA (1) PA8429301A1 (en)
SV (1) SV1997000035A (en)
TN (1) TNSN97084A1 (en)
TW (1) TW381079B (en)
WO (1) WO1997043245A1 (en)
YU (1) YU18697A (en)
ZA (1) ZA974031B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
AR035478A1 (en) * 1999-01-27 2004-06-02 Wyeth Corp AMIDA-HYDROXAMIC ACID, ACETYLLENE, BETA-SULPHONAMIDE AND PHOSPHINIC ACID AS INHIBITORS OF TACE, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
EP1031349A1 (en) * 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
CA2804918C (en) 2010-07-08 2018-03-06 Kaken Pharmaceutical Co., Ltd. N-hydroxyformamide derivative and medicament containing same
CN106458938A (en) 2014-04-03 2017-02-22 拜耳制药股份公司 Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
CA2944614A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases
EP3126339A1 (en) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784701A (en) * 1970-09-21 1974-01-08 American Cyanamid Co Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
DE2112716A1 (en) * 1971-03-17 1972-10-05 Thomae Gmbh Dr K Biphenylyl-butyric acid derivs. - anti phlogistics
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors

Also Published As

Publication number Publication date
CA2253796A1 (en) 1997-11-20
CN1139570C (en) 2004-02-25
CN1225623A (en) 1999-08-11
HRP970245B1 (en) 2002-06-30
ID16910A (en) 1997-11-20
CO5080759A1 (en) 2001-09-25
WO1997043245A1 (en) 1997-11-20
HRP970245A2 (en) 1998-04-30
SV1997000035A (en) 1999-01-14
BR9709077A (en) 1999-08-03
EP0912496A1 (en) 1999-05-06
HN1997000088A (en) 1997-06-18
JPH11511179A (en) 1999-09-28
AU710759B2 (en) 1999-09-30
AU2938697A (en) 1997-12-05
ZA974031B (en) 1998-02-19
AR007097A1 (en) 1999-10-13
YU18697A (en) 1999-11-22
TW381079B (en) 2000-02-01
CA2253796C (en) 2003-10-28
TNSN97084A1 (en) 2005-03-15
JP3090957B2 (en) 2000-09-25

Similar Documents

Publication Publication Date Title
PA8429701A1 (en) INHIBITION OF MATRIX METALOPROTEASES BY SUBSTITUTED BIARILOXOBUTIRIC ACIDS
PA8429301A1 (en) BIARYLACETYLENE AS INHIBITORS OF MATRIX METALOPROTEASE.
PA8456801A1 (en) DERIVATIVES OF ARILOXIARILSULFONILAMINO HIDROXAMICOS ACIDS
CN109152933A (en) Induce the compound of degradation and application thereof of anti-apoptotic BCL-2 family protein
AR014261A1 (en) BENZOTIAZEPINE HYPOLIPIDEMIC COMPOUNDS, COMPOSITIONS AND PROCESS FOR PREPARATION
AR007640A1 (en) DERIVATIVES OF PHENYLALANINE, PROCEDURE TO PREPARE THEM, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM AND USE THEM TO PREPARE A MEDICINAL PRODUCT THAT ACTS AS AN INHIBITOR OF ALPHA INTEGRINE (v)
ES2062943B1 (en) NEW DERIVATIVES OF (2-METHYL-3-PIRIDIL) CYANOMETILPIPERAZINES.
BR9811779A (en) Tetrahydro prostaglandins are replaced by aromatic c16-c20 useful as fp agonists
BR9815596A (en) Compound, pharmaceutical composition, method of treating inflammatory diseases and method of treating condition or disease mediated by mmps and / or tnf and / or agrecanase
ES2183332T3 (en) AROMATIC BICYCLE AMINO ACIDS.
AR003473A1 (en) USE OF L-CARNITINE OR AN ACIL L-CARNITINE WHERE THE ACIL IS SELECTED FROM THE GROUP WHICH INCLUDES ACETYL, PROPIONYL, BUTYRILE, VALERYL AND ISOVALERIL, OR A PHARMACOLOGICALLY ACCEPTABLE SALT FOR THE PRODUCTION OF THE SAME
PA8429801A1 (en) INHIBITION OF MATRIX METALOPROTEASES BY SUBSTITUTED FENETILE COMPOUNDS
ID28365A (en) NEW NATURAL PRODUCTS DOWN
PA8429401A1 (en) SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS
BR9814913A (en) New substance kf-1040 and process for producing it
AR002246A1 (en) NEW SALTS FOR THE ADDITION OF CEFEM ACIDS PROCEDURES FOR THEIR PREPARATION, THE USE OF THE SAME FOR THE PREPARATION OF MEDICINES, AND THE PROCEDURE FOR THE PREPARATION OF SUCH MEDICINAL PRODUCT.
PA8429601A1 (en) INHIBITION OF MATRIX METALOPROTEINASES BY ACIDS 2- (W-AROILALQUIL) -4-BIARIL-4-OXOBUTIRICOS.
NO844889L (en) OKSICAM DERIVATIVES AND PROCEDURES FOR THEIR PREPARATION
ECSP972114A (en) BIARYLACETYLENE AS INHIBITORS OF MATRIX METALOPROTEASE
AR248406A1 (en) Substituted 4-sulphonylamino-2-azinyl-1,2,4-triazol-3-ones, process and intermediates for their preparation and their use as herbicides
ECSP972111A (en) MATRIX METALOPROTEINASES INHIBITORS BY ACIDS 2- (AROILALQUIL) -4 BIARIL-4- OXOBUTIRICOS
PA8510601A1 (en) ETERES OF CALCIUM DICARBOXYLATE, METHODS FOR THE PREPARATION AND TREATMENT OF VASCULAR DISEASES AND DIABETES WITH THE SAME
Follis Jr A survey of bone disease
BRPI0414812A (en) method of inhibiting the expression of multidrug resistant genes and inhibiting the production of proteins resulting from the expression of such genes, thereby improving the effectiveness of chemotherapeutic agents for treating cancer
Pastor et al. Cytotoxicity and mitotic alterations induced by non-genotoxic lithium salts in CHO cells in vitro